peroxisome proliferator–activated receptor agonists
Evolving the Treatment Paradigm in Second-Line Primary Biliary Cholangitis With IQIRVO (elafibranor): A First-in-Class PPAR Agonist
This Special Report discusses considerations for monitoring and treating patients with primary biliary cholangitis ...
APRIL 1, 2025
Elafibranor Significantly Improves Prognosis For Patients With PBC, Study Finds
Elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with ...
FEBRUARY 13, 2025
FDA Approves Elafibranor for Primary Biliary Cholangitis
The FDA granted accelerated approval for elafibranor (Iqirvo, Ipsen), a peroxisome proliferator−activated ...
JUNE 12, 2024
7 Steps to Manage Pruritus in Liver Disease
It’s not just patients with primary biliary cholangitis. Patients with liver disease of all different ...
MAY 23, 2024
Load more